Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Medicus Pharma Ltd ( (MDCX) ) has shared an announcement.
Medicus Pharma will present new Phase I data on its investigational long-acting GnRH antagonist Teverelix at the AACE 2026 meeting, highlighting predictable, dose-dependent estradiol suppression, a long-acting pharmacokinetic profile, and maintenance of bone turnover markers within normal ranges. The therapy was well tolerated in 48 healthy premenopausal women, reinforcing its potential for infrequent dosing and supporting a platform-based strategy across multiple hormone-driven indications in women’s health.
The company is planning a precision medicine program for Teverelix in symptomatic endometriosis, collaborating with Omics Labs in the United Arab Emirates to deploy genomics-enabled patient profiling and biomarker-driven stratification. With no long-acting injectable GnRH antagonists currently approved for endometriosis, Teverelix could secure a first-mover advantage in this high-burden, estrogen-dependent condition and strengthen Medicus Pharma’s positioning in women’s health therapeutics.
The most recent analyst rating on (MDCX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.
Spark’s Take on MDCX Stock
According to Spark, TipRanks’ AI Analyst, MDCX is a Neutral.
The score is primarily held down by weak financial performance, driven by no revenue, widening operating losses, and sharply increasing cash burn that implies ongoing external funding needs, alongside balance-sheet equity volatility. Technicals are also negative with a strong downtrend (price below all key moving averages and negative MACD), only partially tempered by oversold readings. Valuation metrics provide little support because the P/E is not meaningful and no dividend yield is available.
To see Spark’s full report on MDCX stock, click here.
More about Medicus Pharma Ltd
Medicus Pharma Ltd., listed on Nasdaq as MDCX, is a precision-guided biotech and life sciences company advancing novel and potentially disruptive therapeutic assets. Its portfolio includes SkinJect, a localized immuno-oncology product for non-melanoma skin cancers such as basal cell carcinoma and Gorlin Syndrome, and Teverelix, a next-generation GnRH antagonist for hormone-driven conditions, including advanced prostate cancer and women’s health indications.
Average Trading Volume: 4,011,706
Technical Sentiment Signal: Sell
Current Market Cap: $15.82M
For a thorough assessment of MDCX stock, go to TipRanks’ Stock Analysis page.